The Urban Rainforest
Home The Cities eTrade eTourism Archive About Us Contact Us
No Ads
eTrade Contacts
Major ProductsLocation Of SuppliersExport Markets
Trade FairsForeign Buyers GuideEmbassies
Trade Related Government Regulations & PoliciesCalendar Of EventsGovernment Offices Directory
General Info

eTourism Contacts
HospitalsCity FestivalsEmergency Numbers
Tourist OperatorsTourist AttractionsSpecial Areas Of Interest
Accredited Travel AgenciesTourism Related Government Regulations & PoliciesUniversities
TransportationGovernment Tourism OfficesGeneral Info

Calendar of Events Contacts
Cultural Calendar

Cultural Calendar Contacts

eTrade Contacts

News: Novel drug vs hypertension introduced - 08 Mar 2008
For over a decade, no new kind of therapy has been developed to treat high blood pressure (hypertension), a silent killer that afflicts about seven million Filipinos and nearly a billion people worldwide.  

That is, until Swiss pharmaceutical company Novartis AG developed a breakthrough drug that controls hypertension by blocking an enzyme that can trigger the condition.

Aliskiren is the first and only high blood pressure medication that inhibits renin, a kidney enzyme associated with the regulation of blood pressure.

Unlike other available high blood pressure medications that act at later stages of the renin system, a key blood pressure regulation process, Aliskiren, acts at the beginning of this process.

“It is well established that the renin system plays an important role in blood pressure control and is the target of several antihypertensive agents,” said Dr. Matthew Ryan Weir, professor and director of the University of Maryland School of Medicine.

“However, targeting the renin system at its point of activation — renin — has long been regarded as offering the potential for a more comprehensive approach to hypertension and cardiovascular disease treatment,” Weir said.

Weir was the keynote speaker during the Asia-Pacific launch of Aliskiren in a pre-convention satellite symposium during the 13th joint annual convention of the Philippine Society of Hypertension and Philippine Lipid and Atherosclerosis Society.

More than 250 top cardiologists and other specialists attended the launch symposium at the Crowne Plaza Galleria Hotel last Feb. 12.

“The launch of Aliskiren in the Philippines manifests Novartis’ strong commitment to find innovative ways to help doctors care and cure patients with high blood pressure worldwide,” said Peter Goldschmidt, president and CEO of Novartis Healthcare Philippines, Inc.

In most parts of the world, including the Philippines, the rate of uncontrolled hypertension is 85 percent or higher, highlighting the need for more effective and well tolerated antihypertensive drugs. Aliskiren, a direct renin inhibitor (DRI), represents a novel and exciting approach to superior blood pressure control, excellent tolerability, and potential target organ protection either as monotherapy or in combination with other anti-hypertensive medications. In clinical trials involving more than 6,000 people with hypertension, Aliskiren has been shown to consistently lower blood pressure for 24 hours and beyond. 

 “The efficacy of Aliskiren to lower blood pressure for 24 hours and beyond is important because many high blood pressure medications are unable to sustain their blood pressure-lowering effect throughout the day, especially during the early morning hours when blood pressure surges occur,” said Dr. Francis Domingo, Novartis Philippines’ medical director.

In his lecture, Weir cited the results of a randomized clinical trial on Aliskiren and valsartan combination therapy, which showed that despite discontinuation of the drug, blood pressure remained low.

“The blood pressure remained down even after the drug had been discontinued, in some cases, for two to four weeks,” he said. Aliskiren was the gold prize winner of the Wall Street Journal’s seventh annual Technology Innovation Awards held last September.

Editors of the respected business newspaper received more than 800 applications for the award, which was eventually whittled down to 150 entries. A panel of judges from business, research and academic organizations chose winners in 12 categories, along with overall Gold, Silver, and Bronze winners.

To win the award, a technology had to be a breakthrough from traditional methods, not just an incremental improvement. Throughout the clinical trial program, Aliskiren was well tolerated by patients. When used with other anti-hypertension medications such as ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers or diuretics, it delivered additional blood pressure reductions, helping people already on therapy to reach their blood pressure goals.

Aliskiren was also well tolerated when used with the most common diabetic and cardiovascular medications.An extensive clinical program (ASPIRE HIGHER) is currently evaluating the long-term potential of Aliskiren and direct renin inhibition in patients with cardiovascular or kidney disease.Aliskiren is a prescription medicine and should only be taken upon a doctor’s advice. Aliskiren has also been approved in more than 40 countries and used in more than 130,000 patients worldwide.

Source:, Thursday, March 6, 2008

Posted By: PhilCTTIS Data Center 
Date  Title  Action
30 Sep 2010  BUSINESS DIRECTORY: Gifts and Christmas Decors  View
29 Sep 2010  List of State Universities and Colleges in NCR  View
27 Sep 2010  DIRECTORY: Suppliers of IT & IT Enabled Services/Electronics  View
23 Sep 2010  DIRECTORY: Suppliers of Processed Food  View
21 Sep 2010  DIRECTORY: Domestic Suppliers of Accessories (NCR)  View
07 Aug 2010  Brief History of Pasig  View
15 Feb 2008  Important Numbers to Remember  View
15 Nov 2007  Let?s kill poverty  View
01 Oct 2007  Guide to Honeybee Processors  View
24 Aug 2010  Important Events to Remember  View
22 Mar 2011  EEI profit soars 17% to P657 M  View
19 Mar 2011  Foreign investors interested in opening 20 branches  View
03 Dec 2010  ADB to invest in Asia’s water infrastructure  View
13 Oct 2010  NEDA: RP August exports among Southeast Asia’s highest  View
29 Aug 2010  NEDA pushes public-private partnership  View
27 Aug 2010  ADB offers $280-million loan to boost RP's clean air program   View
17 Aug 2010  Jollibee Profit Reaches P1.43 B  View
06 Aug 2010  JG Summit ventures into BPO business  View
02 Aug 2010  San Miguel Pursues Laiban Project  View
08 May 2008  9 scientists, NGO get biotech awards  View
04 May 2008  Online trading spawns new breed of stock investors here  View
27 Apr 2008  SMB prices IPO at P8 per share  View
08 Mar 2008  Novel drug vs hypertension introduced  View
01 Mar 2008  RP firms eye slice of $12-B ME food mart  View
17 Feb 2008  Low-dose aspirin safe for heart protection  View
17 Feb 2008  Estanislao: 65% of PSE-listed co?s now on a par with HK, Thailand  View
17 Feb 2008  Private sector gives P4B for public school projects  View
23 Jan 2008  Suez-Tractebel seeks loans to finance Calaca acquisition  View
12 Jan 2008  ePerformax gets SEC approval for P3.345-B initial public offer  View
18 Nov 2007  SEIPI implements 7 key initiatives to raise electronics exports to $ 45 B  View
01 Nov 2007  Sy sells San Miguel stake  View
28 Oct 2007  Belle Corp posts higher net income of P140M  View
28 Oct 2007  Greenfield Development benefits from boom in business process outsourcing  View
20 Oct 2007  SEC okays PAL Holdings? restructuring  View
20 Oct 2007  Index gains amid solid corporate earnings  View
No Ads
Logos and trademarks are the property of their respective owners.
Philippine Cities Trade & Tourism Information Service (c) Copyright 2007, all rights reserved.